Condensed Consolidated Statements of Operations (Unaudited) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Revenues:
Product royalties	$ 11,832	$ 924,272	$ 1,857,920	$ 1,779,373
Research and development reimbursements	1,297,761		12,067,324
Contract revenues	512,774	2,072,590	22,471,502	5,603,516
Total Revenues:	1,822,367	2,996,862	36,396,746	7,382,889
Cost of sales	462,802	643,486	1,875,365	1,708,693
Expenses:
Research and development	6,769,698	16,387,194	29,375,895	41,177,577
Selling, general and administrative	13,648,648	3,049,005	25,532,632	9,099,515
Total Expenses:	20,418,346	19,436,199	54,908,527	50,277,092
Loss from operations	(19,058,781)	(17,082,823)	(20,387,146)	(44,602,896)
Interest expense, net	(514,718)	(450,328)	(1,588,736)	(281,812)
Derivative (loss) gain	(5,684,893)	(917,863)	(14,630,675)	499,671
Other income (expense), net	2,134	(35,433)	34,519	(154,061)
Net loss before taxes	(25,256,258)	(18,486,447)	(36,572,038)	(44,539,098)
Income tax expense	0		0	(85,000)
Net loss attributable to common stockholders	$ (25,256,258)	$ (18,486,447)	$ (36,572,038)	$ (44,624,098)
Basic earnings per share:	$ (0.51)	$ (0.49)	$ (0.77)	$ (1.18)
Diluted earnings per share:	$ (0.51)	$ (0.49)	$ (0.77)	$ (1.18)
Weighted average common stock shares outstanding	49,555,815	38,076,606	47,391,040	37,864,248